PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-2.87%
Negative revenue growth while AVGO stands at 6.32%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
3.04%
Gross profit growth at 50-75% of AVGO's 4.96%. Martin Whitman would question if cost structure or brand is lagging.
55.04%
Positive EBIT growth while AVGO is negative. John Neff might see a substantial edge in operational management.
55.04%
Operating income growth above 1.5x AVGO's 1.00%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
280.21%
Positive net income growth while AVGO is negative. John Neff might see a big relative performance advantage.
333.33%
Positive EPS growth while AVGO is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
333.33%
Positive diluted EPS growth while AVGO is negative. John Neff might view this as a strong relative advantage in controlling dilution.
No Data
No Data available this quarter, please select a different quarter.
-6.68%
Reduced diluted shares while AVGO is at 0.70%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
88.98%
OCF growth above 1.5x AVGO's 9.32%. David Dodd would confirm a clear edge in underlying cash generation.
58.42%
FCF growth above 1.5x AVGO's 9.56%. David Dodd would verify if the firm’s strategic investments yield superior returns.
241.96%
10Y revenue/share CAGR at 50-75% of AVGO's 416.86%. Martin Whitman would question if the firm’s offerings lag behind the competitor.
241.96%
5Y revenue/share CAGR above 1.5x AVGO's 134.28%. David Dodd would look for consistent product or market expansions fueling outperformance.
116.71%
3Y revenue/share CAGR above 1.5x AVGO's 62.33%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
-116.65%
Negative 10Y OCF/share CAGR while AVGO stands at 580.47%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-116.65%
Negative 5Y OCF/share CAGR while AVGO is at 92.77%. Joel Greenblatt would question the firm’s operational model or cost structure.
-106.12%
Negative 3Y OCF/share CAGR while AVGO stands at 39.51%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
53.94%
Below 50% of AVGO's 869.72%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
53.94%
Below 50% of AVGO's 414.43%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
-22.07%
Negative 3Y CAGR while AVGO is 16.00%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
684.61%
10Y equity/share CAGR at 75-90% of AVGO's 862.23%. Bill Ackman would push for either higher ROE or more earnings retention to catch the competitor.
684.61%
5Y equity/share CAGR above 1.5x AVGO's 165.61%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
159.52%
3Y equity/share CAGR at 75-90% of AVGO's 201.93%. Bill Ackman pushes for margin or operational changes to match the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
24.58%
Our AR growth while AVGO is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
-10.19%
Inventory is declining while AVGO stands at 8.08%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-4.07%
Negative asset growth while AVGO invests at 0.60%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
4.11%
75-90% of AVGO's 5.15%. Bill Ackman advocates improvements in profitability or buybacks to keep pace in net worth growth.
-42.16%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-1.45%
Our R&D shrinks while AVGO invests at 13.26%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
0.43%
We expand SG&A while AVGO cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.